About
Rhythm Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 1 2026
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
Apr 9 2026
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Apr 3 2026
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Mar 26 2026
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Recent Videos

RYTM, Rhythm Pharmaceuticals, Inc. stock prices historical data
Apr 26, 2026

24-6954 ACTCA, a Member of the Alliance, Inc. v. Rhythm Pharmaceuticals, Inc., et al.
Apr 24, 2026

26 Marzo 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Mar 26, 2026

26 March 26. Biotech Stock News. Daily Recap2 #English #Shorts $XBI #trading #biotechnews #dailynews
Mar 26, 2026
Translate